Chemomab Therapeutics Ltd.(CMMB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CMMB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Chemomab Therapeutics Ltd. (CMMB), a Healthcare sector company. CMMB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (FY 2025), Chemomab Therapeutics Ltd. reports net income of $-9.0M, free cash flow of $-11.1M. Top institutional holders of CMMB by reported 13-F value include ADAR1 Capital Management,, CITADEL ADVISORS, KESTRA PRIVATE WEALTH SERVICES,, based on the most recent SEC filings. CMMB trades on the Nasdaq exchange and files with the SEC under CIK 1534248. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CMMB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Chemomab Therapeutics Ltd. directly from SEC EDGAR.
Net Income
FY 2025
$-9.0M
Free Cash Flow
FY 2025
$-11.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-96.6% YoYTotal Assets
+54.8% YoYOp. Cash Flow
-15.7% YoY| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Net Income | $-27.1M -96.6% | $-13.8M |
| Total Assets | $19.8M +54.8% | $12.8M |
| Operating Cash Flow | $-16.5M -15.7% | $-14.2M |
Get alerted when CMMB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Chemomab Therapeutics Ltd. including:
Top Institutional Holders of CMMB
ADAR1 Capital Management, LLC
$125.6K80,000 shCITADEL ADVISORS LLC
$100.8K64,182 shKESTRA PRIVATE WEALTH SERVICES, LLC
$96.9K61,710 shIkarian Capital, LLC
$81.3K51,793 shXTX Topco Ltd
$29.2K18,629 shRHUMBLINE ADVISERS
$28.8K18,366 shSmartHarvest Portfolios, LLC
$22.9K14,566 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$21.2K13,491 shBNP PARIBAS FINANCIAL MARKETS
$13.2K8,425 shPhiladelphia Investment Partners, LLC
$12.9K8,200 sh
| Fund | Value | Shares |
|---|---|---|
| ADAR1 Capital Management, LLC | $125.6K | 80,000 |
| CITADEL ADVISORS LLC | $100.8K | 64,182 |
| KESTRA PRIVATE WEALTH SERVICES, LLC | $96.9K | 61,710 |
| Ikarian Capital, LLC | $81.3K | 51,793 |
| XTX Topco Ltd | $29.2K | 18,629 |
| RHUMBLINE ADVISERS | $28.8K | 18,366 |
| SmartHarvest Portfolios, LLC | $22.9K | 14,566 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $21.2K | 13,491 |
| BNP PARIBAS FINANCIAL MARKETS | $13.2K | 8,425 |
| Philadelphia Investment Partners, LLC | $12.9K | 8,200 |
More Healthcare Companies
View all Healthcare →Put CMMB on your watchlist
Track score changes the day Chemomab Therapeutics Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CMMB a good stock to buy?
13F Pro's AI-powered analysis of Chemomab Therapeutics Ltd. (CMMB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CMMB are available on the CMMB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CMMB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CMMB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Chemomab Therapeutics Ltd.'s investment landscape.